Win-552122

Win-552122

SCHEMBL118531

Cc1c(C(=O)c2cccc3ccccc23)c2cccc3c2n1[C@H](CN1CCOCC1)CO3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 8/20 1.00
CNR2 P34972 8/20 1.00
ALDH1A1 P00352 3/20 1.00
MAPT P10636 1/20 1.00
NPC1 O15118 1/20 1.00
MTOR P42345 1/20 1.00
RAB9A P51151 1/20 1.00
CYP3A4 P08684 2/20 0.92
CYP2C9 P11712 2/20 0.92
RGS12 O14924 1/20 0.92
GMNN O75496 1/20 0.92
LMNA P02545 1/20 0.92
TP53 P04637 1/20 0.92
CYP2D6 P10635 1/20 0.92
ALOX15 P16050 1/20 0.92
NFKB1 P19838 1/20 0.92
MAPK1 P28482 1/20 0.92
CYP2C19 P33261 1/20 0.92
THPO P40225 1/20 0.92
BLM P54132 1/20 0.92

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Win-552122 SCHEMBL29611661 1.00 CNR1 (1.00) CNR1CNR2ALDH1A1MAPTNPC1
Win-552122 SCHEMBL3680086 1.00 CNR1 (1.00) CNR1CNR2ALDH1A1MAPTNPC1
Win-552122 SCHEMBL29361053 1.00 CNR1 (1.00) CNR1CNR2ALDH1A1MAPTNPC1
Win-552122 SCHEMBL29410177 1.00 CNR1 (1.00) CNR1CNR2ALDH1A1MAPTNPC1
Win-552122 SCHEMBL29381882 1.00 CNR1 (1.00) CNR1CNR2ALDH1A1MAPTNPC1
Win-552122 SCHEMBL10093015 1.00 CNR1 (1.00) CNR1CNR2ALDH1A1MAPTNPC1
Win-552122 SCHEMBL31338445 0.98 CNR1 (0.96) CNR1CNR2ALDH1A1MAPTNPC1
Win-552122 SCHEMBL1517636 0.96 CNR1 (1.00) CNR1CNR2ALDH1A1MAPTNPC1
Win-552122 SCHEMBL8071465 0.96 CNR1 (1.00) CNR1CNR2ALDH1A1MAPTNPC1
Win-552122 SCHEMBL29496357 0.96 CNR1 (1.00) CNR1CNR2ALDH1A1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858649-B1 TREATMENT OF MOTOR AND MOVEMENT DISORDER SIDE EFFECTS ASSOCIATED WITH PARKINSON'S DISEASE TREATMENTS PSYCHOGENICS INC (US) 2019-10-23 EP claimed
US-20190142788-A1 USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS INMED PHARMACEUTICALS INC. (CA) 2019-05-16 US claimed
WO-2013025984-A2 CANNABINOID RECEPTOR TREATMENTS TEMPLE UNIVERSITY (US) 2013-02-21 WO claimed
US-20120202891-A1 Cannabinoid-Containing Compositions and Methods for Their Use UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2012-08-09 US claimed
EP-1785130-A2 Hair and/or scalp treatment compositions Unilever PLC (GB) 2007-05-16 EP claimed
EP-1406576-A1 HAIR AND/OR SCALP TREATMENT COMPOSITIONS UNILEVER PLC (GB) 2004-04-14 EP claimed
US-20030049220-A1 Hair and/or scalp treatment compositions UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2003-03-13 US claimed
WO-2003007901-A1 HAIR AND/OR SCALP TREATMENT COMPOSITIONS UNILEVER PLC (GB) 2003-01-30 WO claimed
US-6503492-B2 Antiperspirant or deodorant compositions UNILEVER HOME & PERSONAL CARE USA, A DIVISION OF CONOPCO, INC. 2003-01-07 US claimed
US-20020182159-A1 ANTIPERSPIRANT OR DEODORANT COMPOSITIONS UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2002-12-05 US claimed
US-20260131008-A1 HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS CELLA THERAPEUTICS LLC (US) 2026-05-14 US disclosed
US-20250302771-A1 TREATMENT OF OPIOID USE DISORDER, OPIOID WITHDRAWAL SYMPTOMS AND CHRONIC PAIN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-10-02 US disclosed
US-20250283122-A1 BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS GINKGO BIOWORKS, INC. (US) 2025-09-11 US disclosed
US-20250170152-A1 Cannabinoid Dosage Form Emyria (AU) 2025-05-29 US disclosed
US-20250064713-A1 COSMETIC COMPOSITIONS ELEBLEND LLC (US) 2025-02-27 US disclosed
US-20030049220-A1 Hair and/or scalp treatment compositions UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2003-03-13 US disclosed
WO-2003007901-A1 HAIR AND/OR SCALP TREATMENT COMPOSITIONS UNILEVER PLC (GB) 2003-01-30 WO disclosed
US-6503492-B2 Antiperspirant or deodorant compositions UNILEVER HOME & PERSONAL CARE USA, A DIVISION OF CONOPCO, INC. 2003-01-07 US disclosed
US-20020182159-A1 ANTIPERSPIRANT OR DEODORANT COMPOSITIONS UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2002-12-05 US disclosed
US-20020111377-A1 Transdermal delivery of cannabinoids ALBANY COLLEGE OF PHARMACY 2002-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250064713-A1 COSMETIC COMPOSITIONS CUTA, SUCLG1, ASAH2 CNR1 2691/4885CNR2 2053/4885ALDH1A1 874/4885
US-20260131008-A1 HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS SLC26A6, SLC26A3, SLC9A2 CNR1 1606/4885CNR2 1399/4885ALDH1A1 979/4885
US-20120202891-A1 Cannabinoid-Containing Compositions and Methods for Their Use CNR2, CNR1, FAAH CNR1 2/4885CNR2 1/4885ALDH1A1 3754/4885
US-20190142788-A1 USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS KRT18, DSP, DSC1 CNR1 60/4885CNR2 28/4885ALDH1A1 4687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.